QQ客服 官方微博 反馈留言

	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
	Qu, Yiqing; Wu, Xiuxiu; Yin, Yunhong; Yang, Yan; Ma, Dedong; Li, Hao
刊名	JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
	2014
卷号	33
关键词	AZD6244 BEZ235 Tyrosine kinase inhibitor Non small cell lung cancer
DOI	10.1186/1756-9966-33-52
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4793940
专题	山东大学
作者单位	Shandong Univ, Qilu Hosp, Dept Resp Med, Jinan 250012, Peoples R China.
推荐引用方式 GB/T 7714	Qu, Yiqing,Wu, Xiuxiu,Yin, Yunhong,et al. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models[J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2014,33.
APA	Qu, Yiqing,Wu, Xiuxiu,Yin, Yunhong,Yang, Yan,Ma, Dedong,&Li, Hao.(2014).Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,33.
MLA	Qu, Yiqing,et al."Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 33(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。